--- title: "Sunshine Biopharma (SBFM) news: offering and Nasdaq notice" url: "https://aibio.space/companies/sunshine-biopharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SBFM offering and Nasdaq notice news: Sunshine Biopharma files for $7,000,000 unit offering, later priced at $0.55 per unit. Sunshine Biopharma Inc." --- SBFM Sunshine Biopharma Inc. NASDAQ · United States # Sunshine Biopharma (SBFM) news SBFM offering and Nasdaq notice news Financings · 2026-10-02 ## [Sunshine Biopharma files for $7,000,000 unit offering, later priced at $0.55 per unit](https://aibio.space/news/sunshine-biopharma-files-7-000-000-unit-offering-later-priced-0-55/) A preliminary prospectus dated October 2, 2026 set out a best efforts offering of units with Series D warrants. The deal was later priced to raise about $6.0 million before fees. ## Latest Sunshine Biopharma news 1. 2026-07-20 Financings [Sunshine Biopharma sets up $4,000,000 at-the-market stock sale with Aegis Capital](https://aibio.space/news/sunshine-biopharma-sets-up-4-000-000-market-stock-sale-aegis-capital/) Sunshine Biopharma Inc. signed an at-the-market sales agreement with Aegis Capital Corp. under which it may sell up to $4,000,000 of common stock, with Aegis as exclusive sales agent. 2. 2026-05-18 Financings [Sunshine Biopharma prices $6.0 million public offering of units and Series C warrants](https://aibio.space/news/sunshine-biopharma-prices-6-0-million-public-offering-units-series/) The reasonable best efforts offering of 12,000,000 common units at $0.50 per unit is expected to close on or about May 19, 2026, with Aegis Capital Corp. as exclusive placement agent. 3. 2026-04-06 Company Updates [Sunshine Biopharma reports fiscal 2025 revenue of $36.3 million](https://aibio.space/news/sunshine-biopharma-reports-fiscal-2025-revenue-36-3-million/) The company says 2025 revenue rose 4.1% and its net loss was $5.98 million, which it attributes partly to a $1.75 million impairment charge, and it expects cost cuts of $2 million to $3 million in 2026. 4. 2026-03-31 Distress [Sunshine Biopharma files NT 10-K, says annual report will be late](https://aibio.space/news/sunshine-biopharma-files-nt-10-k-says-annual-report-will-late/) Sunshine Biopharma filed a Form 12b-25 on March 31, 2026 for its 10-K for the year ended December 31, 2025. It cites time constraints and says it will file no later than fifteen days after the original due date. Its 2024 net loss was $5,134,116. 5. 2025-03-31 Distress [Sunshine Biopharma files NT 10-K late-filing notice for 2024 annual report](https://aibio.space/news/sunshine-biopharma-files-nt-10-k-late-filing-notice-2024-annual-report/) The company says it needs additional time to complete its financial statements for the period ended December 31, 2024. It checked the box for filing within the fifteenth calendar day after the due date. 6. 2025-03-31 Distress [Sunshine Biopharma files late notice for annual report for December 31, 2024](https://aibio.space/news/sunshine-biopharma-files-late-notice-annual-report-december-31-2024/) The Fort Lauderdale company said it needs more time to complete its financial statements. It does not expect a significant change in results. ## Sunshine Biopharma at a glance - **Ticker**: SBFM - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $13.7 million ### Related companies - [Amylyx Pharmaceuticals](https://aibio.space/companies/amylyx-pharmaceuticals/) NASDAQ: AMLX - [Integrated BioPharma](https://aibio.space/companies/integrated-biopharma/) OTC: INBP - [Kaleido Biosciences](https://aibio.space/companies/kaleido-biosciences/) OTC: KLDO - [Azitra](https://aibio.space/companies/azitra/) AMEX: AZTR - [Biohaven](https://aibio.space/companies/biohaven/) NYSE: BHVN - [Skinvisible](https://aibio.space/companies/skinvisible/) OTC: SKVI - [Sutro Biopharma](https://aibio.space/companies/sutro-biopharma/) NASDAQ: STRO - [Annovis Bio](https://aibio.space/companies/annovis-bio/) NYSE: ANVS ### Also on NASDAQ - [Bioventus](https://aibio.space/companies/bioventus/) BVS - [Mangoceuticals](https://aibio.space/companies/mangoceuticals/) MGRX - [Lantheus Holdings](https://aibio.space/companies/lantheus/) LNTH - [NATURES SUNSHINE PRODUCTS INC](https://aibio.space/companies/natures-sunshine-products/) NATR - [Prothena Corporation](https://aibio.space/companies/prothena/) PRTA - [Medicus Pharma](https://aibio.space/companies/medicus-pharma/) MDCX ## What Sunshine Biopharma does Sunshine Biopharma Inc. is a pharmaceutical company offering and researching medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its Canadian subsidiary Nora Pharma Inc., it has 71 generic prescription drugs on the market in Canada. Nora Pharma obtains rights through in-licensing and supply agreements, cross-licensing or distribution agreements, and files with Health Canada where needed. Its other subsidiary, Sunshine Biopharma Canada Inc., develops and sells OTC supplements. The company's proprietary drug development program includes K1.1 mRNA, an LNP encapsulated mRNA targeted for liver cancer, and SBFM-PL4, a protease inhibitor for SARS Coronavirus infections. Both are in animal testing. The company has 22 additional drugs in its pipeline, including 12 it anticipates launching during the remainder of 2026. It cites the Canadian $10.4 billion a year generic drugs market. | Product or program | What it is | Stage | |---|---|---| | Generic prescription drugs (Nora Pharma) | Generic medicines sold in Canada under its own or partners' labels | 71 on the market in Canada | | K1.1 mRNA | LNP encapsulated mRNA targeted for liver cancer | Animal Testing | | SBFM-PL4 | Protease inhibitor for SARS Coronavirus infections | Animal Testing | | OTC supplements (Sunshine Biopharma Canada) | Over-the-counter supplements developed and sold by the Canadian subsidiary | Sold | Summarised from the company's [10-K filed Apr 3, 2026](https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm). ## Sunshine Biopharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$36.3 million](https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/) | [$34.9 million](https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/) | | Research and development | [$604,308](https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/) | [$933,902](https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/) | | Net income (loss) | [-$6.0 million](https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/) | [-$5.1 million](https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/) | | Cash from operations | [-$5.3 million](https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/) | [-$12.5 million](https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/) | | Cash and equivalents | [$9.1 million](https://www.sec.gov/Archives/edgar/data/1402328/000168316826006340/) | [$9.7 million](https://www.sec.gov/Archives/edgar/data/1402328/000168316826006340/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $13.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Sunshine Biopharma Has Sunshine Biopharma raised money recently? Our latest story on this, dated Oct 2, 2026: "Sunshine Biopharma files for $7,000,000 unit offering, later priced at $0.55 per unit". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sunshine-biopharma-files-7-000-000-unit-offering-later-priced-0-55/). Has Sunshine Biopharma received a Nasdaq deficiency notice? Our latest story on this, dated Mar 31, 2025: "Sunshine Biopharma files NT 10-K late-filing notice for 2024 annual report". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sunshine-biopharma-files-nt-10-k-late-filing-notice-2024-annual-report/). What is the ticker symbol of Sunshine Biopharma? Sunshine Biopharma Inc. trades under the ticker SBFM on NASDAQ. Where is Sunshine Biopharma listed? Sunshine Biopharma Inc. is listed on NASDAQ. What is the SEC CIK of Sunshine Biopharma? The SEC Central Index Key (CIK) for Sunshine Biopharma Inc. is 1402328. Its filings are on SEC EDGAR. How many shares does Sunshine Biopharma have outstanding? 3,877,337 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Sunshine Biopharma listed under? Our directory records Sunshine Biopharma Inc. under United States. What does Sunshine Biopharma do? Our directory classifies Sunshine Biopharma Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Sunshine Biopharma? The ISIN recorded for Sunshine Biopharma Inc. is US8677818093. Does aibio.space cover Sunshine Biopharma? aibio.space lists Sunshine Biopharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Sunshine Biopharma incorporated? SEC records list its state or country of incorporation as CO. What does Sunshine Biopharma develop? Sunshine Biopharma Inc. is a pharmaceutical company offering and researching medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its Canadian subsidiary Nora Pharma Inc., it has 71 generic prescription drugs on the market in Canada. What is Generic prescription drugs (Nora Pharma) from Sunshine Biopharma? Generic prescription drugs (Nora Pharma): Generic medicines sold in Canada under its own or partners' labels Stage: 71 on the market in Canada. What is K1.1 mRNA from Sunshine Biopharma? K1.1 mRNA: LNP encapsulated mRNA targeted for liver cancer Stage: Animal Testing. What was Sunshine Biopharma's revenue last year? $36.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Sunshine Biopharma Members talk about Sunshine Biopharma (SBFM). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Sunshine Biopharma, newest first. Each line links the filing it comes from. 1. 2026-10-02 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007581/sunshine_s1.htm) 2. 2026-09-16 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007193/sunshine_8k.htm) 3. 2026-08-28 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316826006779/sunshine_s1.htm) 4. 2026-05-12 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316826003726/sunshine_s1.htm) 5. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316826002539/sunshine_ext.htm) 6. 2026-03-09 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316826001609/sunshine_ex9901.htm) 7. 2026-02-20 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316826001216/sunshine_8k.htm) 8. 2025-09-30 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316825007338/sunshine_8k.htm) 9. 2025-08-05 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316825005644/sunshinebio_s1.htm) 10. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316825002126/sunshine_ext.htm) 11. 2025-01-06 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316825000107/sunshine_s3.htm) 12. 2024-11-12 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1402328/000168316824007865/sunshine_424b4.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SBFM on TradingView](https://www.tradingview.com/symbols/NASDAQ-SBFM/). ## SEC filings and registration - **SEC name**: Sunshine Biopharma Inc. - **CIK**: 1402328 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SBFM (Nasdaq), SBFMW (Nasdaq) - **State or country of incorporation**: CO - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 333 LAS OLAS WAY, FORT LAUDERDALE, FL, 33301 - **Phone**: 954-330-0684 - **Shares outstanding**: 3,877,337 as of 2026-08-13 (10-Q filed 2026-08-13) - **Former names**: Sunshine Biopharma, Inc; Mountain West Business Solutions, Inc; mountain west business solutions,inc ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007845/sunshine_8k.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007758/sunshine_8k.htm) filed 2026-10-09 - [S-1](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007581/sunshine_s1.htm) filed 2026-10-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007193/sunshine_8k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1402328/000168316826007090/sunshine_8k.htm) filed 2026-09-11 - [S-1](https://www.sec.gov/Archives/edgar/data/1402328/000168316826006779/sunshine_s1.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1402328/000168316826006777/sunshine_8k.htm) filed 2026-08-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1402328/000168316826006340/sunshine_i10q-063026.htm) filed 2026-08-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001402328), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Sunshine Biopharma Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SBFM, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Sunshine Biopharma Inc. - **Ticker**: SBFM - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US8677818093 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SBFM/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/sunshine-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sunshine Biopharma (SBFM) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/sunshine-biopharma/